CJC-1295 + Ipamorelin (5mg+5mg)

CJC-1295 + Ipamorelin: A dual-mechanism growth hormone research blend combining CJC-1295 (without DAC)
and Ipamorelin in equal ratios. This combination is one of the most referenced
GH secretagogue pairings in pituitary function and somatotropic axis research.

Blend Composition (per vial):
— CJC-1295 No DAC (Growth Hormone Releasing Hormone Analog): 5mg
— Ipamorelin (Growth Hormone Secretagogue / Ghrelin Mimetic): 5mg
— Total: 10mg
— Form: Lyophilized powder

CJC-1295 and Ipamorelin operate on entirely different receptor systems, making
this combination uniquely valuable in GH axis research. CJC-1295 acts on GHRH
receptors in the anterior pituitary, stimulating GH release through the natural
hypothalamic pathway. Ipamorelin targets GHS-R1a (ghrelin receptors), suppressing
somatostatin while producing a clean GH pulse with minimal effect on cortisol
or prolactin. Together they produce synergistic GH output — studies suggest the
combined GH pulse is 3–5x greater than either compound alone. Researchers studying
the somatotropic axis, IGF-1 modulation, sleep architecture, and body composition
models use this blend as the standard dual-pathway GH stimulation model.

Supplied lyophilized in a sterile sealed vial. Third-party tested for identity
and purity prior to release. Not for human consumption. For research use only.